Growth Metrics

Integra Lifesciences Holdings (IART) Amortization of Deferred Charges (2016 - 2019)

Integra Lifesciences Holdings' Amortization of Deferred Charges history spans 11 years, with the latest figure at $1.3 million for Q4 2019.

  • For Q4 2019, Amortization of Deferred Charges fell 0.84% year-over-year to $1.3 million; the TTM value through Dec 2019 reached $5.3 million, down 15.63%, while the annual FY2019 figure was $5.4 million, 14.04% down from the prior year.
  • Amortization of Deferred Charges for Q4 2019 was $1.3 million at Integra Lifesciences Holdings, down from $1.4 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.1 million in Q2 2018 and bottomed at $391000.0 in Q2 2017.
  • The 5-year median for Amortization of Deferred Charges is $762500.0 (2015), against an average of $965937.5.
  • The largest annual shift saw Amortization of Deferred Charges tumbled 36.2% in 2017 before it soared 446.8% in 2018.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $619000.0 in 2015, then skyrocketed by 46.37% to $906000.0 in 2016, then soared by 70.42% to $1.5 million in 2017, then fell by 14.7% to $1.3 million in 2018, then fell by 0.84% to $1.3 million in 2019.
  • Per Business Quant, the three most recent readings for IART's Amortization of Deferred Charges are $1.3 million (Q4 2019), $1.4 million (Q3 2019), and $1.3 million (Q4 2018).